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knowledge regarding late effects comes from studies in adult
recipients or hospital based studies where duration or reli-
ability of follow-up data is limited. The aim of our study was
to examine the risk of second malignancy and late mortality
in a population-based cohort of pediatric recipients of allo-
geneic hematopoietic stem cell transplant (HSCT) in
Australia.
Methods: Australian pediatric allogeneic HSCT recipients
aged less than 15 years and treated for a hematological
malignancy from 1982-2007, were identiﬁed from pediatric
hospitals and the Australasian Bone Marrow Transplant
Recipient Registry (ABMTRR). Patient records were linked to
records held by the Australian Cancer Database (ACD) and
National Death Index to determine second cancers and
deaths in the cohort. Standardized rates (SIRs & SMRs) and
risk factors were characterised for second malignancies
following HSCT and late deaths (deaths occurring 2 or more
years after HSCT).
Results: Second cancers were observed in 17 of the 674
(2.5%) HSCT recipients with a primary cancer diagnosis
recorded on the ACD. Thyroid cancer was the most
common second cancer observed (n¼8) followed by brain
tumours (n¼4). The rate of second cancers occurring after
HSCT was 20 times higher than expected based on rates in
the age-, sex- and calendar-year matched general pop-
ulation (SIR¼20.33, 95% CI¼12.64-32). Total body irradia-
tion was associated with a 4-fold increased risk of
secondary malignancy, while non-Hodgkin lymphoma
patients were 7 times more likely to develop a second
malignancy compared to acute lymphoblastic leukaemia
patients.
While the overall rate of late death was 36 times greater
than the rate seen in the age-, sex- and calendar-year
matched general population (SMR¼35.93, 95%CI¼26.74-
48.29), rates of death returned to levels similar to the general
population 10 years after HSCT.
Conclusions: This is the ﬁrst study to use population-based
registry data to determine the risk of second cancer and late
death in pediatric patients with a hematologic cancer treated
by allogeneic HSCT. The increased risk of second cancer and
late deaths in this population highlights the importance of
long-term follow up, surveillance and early detection of
second cancer.Table
Associations between HCT-CI risk groups and dichotomized outcomes of
QOL among 398 long-term HCT survivors
Dichotomized outcomes
based on standard cutoffs
from population norms
HCT-
CI 0
HCT-
CI 1-2
HCT-
CI 3
Adjusted
P-trend
% % %
SCL-90-R depression 20 >1.74 3 7 9 0.04
CTXD distress >1.11 15 21 23 0.04
ESSI social support < 13.8 11 13 21 0.02
SRCI general health score > 2 31 38 60 0.0005
Logistic regression model: adjusted for age, gender diagnoses, disease
status, CMV sero-status, conditioning intensity, doner type, and stem cell
source + self-reported race, location per state, rural vs. urban, and years post
HCT + relapse.79
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Whether pre-transplant comorbidities are associated
with QOL after allogeneic HCT is unknown.We used the HCT-
comorbidity index (CI) in order to investigate possibleassociations of baseline comorbidities with different
domains of QOL among long-term survivors.
All survivors >17 years of age, who were 3-18 years after
HCT for hematological malignancy, without active cancers
for 2 years, and with internet access were eligible for the
study and hence were approached by mail for participation.
Assessment was conducted with an online survey that
collected information on socioeconomic status, the Short-
Form Health Survey (SF-36), Fatigue Symptom Inventory
(FSI), Symptom Check List-90-Revised (SCL-90-R) for
depression, Cancer and Treatment Distress (CTXD) scale,
ENRICHD Social Support Instrument (ESSI), Social Activity
Log (SAL), and self-reported comorbidity index (SR-CI) for
general health.
Of 1,775 participants approached for the study, 775 were
eligible, consented and completed the assessments, of whom
588 were recipients of allogeneic HCT, of whom 398 were
given HLA-matched grafts and contributed to this study.
Median age at HCT was 43 (3-76) years and median time
from HCT was 7.5 (3.1-17.2) years. Diagnoses were mostly
myeloid (83%) or lymphoid (16%) malignancies. Baseline
HCT-CI scores were 0 vs. 1-2 vs. 3 in 47%, 35%, and 18% of
survivors, respectively. High-intensity conditioning regi-
menswere used in 88% of the survivors, and grafts were from
related donors in 55% of survivors. Rate of post-HCT relapse
was 11%.
Linear and logistic regression models were adjusted for
pre-transplant characteristics, socioeconomic factors, and
relapse after HCT. When scores of QOL measures were
assessed on a continuous scale, HCT-CI scores of 0 vs. 1-2, vs.
3 were associated with impaired physical health as
evidences by decreasing means (SD) of 48.9 (10.4) vs. 47.2
(11.2) vs. 44.9 (10.4), respectively, of the physical component
score of the SF-36 (P ¼ 0.04). Other QOL measures were
assessed as dichotomized outcomes based on standard cut-
offs of the population norm. Higher HCT-CI scores were
signiﬁcantly associated with increased depression, increased
distress from cancer or its treatment, diminished social
support, and higher comorbidity burden among long-term
survivors (Table). HCT-CI scores were not associated with the
mental component of the SF-36, increased fatigue, or social
activities.
This is, to the best of our knowledge, the ﬁrst evidence
that pre-transplant comorbidities, captured by a prognostic
comorbidity index, were associated with long-term QOL
outcomes for survivors after allogeneic HCT. Prospective
studies are warranted to explore associations of comorbid-
ities with QOL early after HCT and to evaluate preventive or
rehabilitation interventions that might improve long-term
QOL for survivors, particularly those with high pretransplant
comorbidity burden.
